Abstract

Breaking Insights| March 02 2023 Highlights from Recent Cancer Literature Author & Article Information Online ISSN: 1538-7445 Print ISSN: 0008-5472 ©2023 American Association for Cancer Research2023American Association for Cancer Research Cancer Res (2023) 83 (5): 653–654. https://doi.org/10.1158/0008-5472.CAN-83-5-BI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record March 2 2023 Citation Highlights from Recent Cancer Literature. Cancer Res 1 March 2023; 83 (5): 653–654. https://doi.org/10.1158/0008-5472.CAN-83-5-BI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Despite hundreds of trials examining the combination of radiotherapy with immunotherapy, evidence for synergy as well as predictive biomarkers are lacking. Spurr and colleagues conducted a trial to examine the efficacy of the combination of immunotherapy plus multisite ablative radiotherapy in non-small cell lung cancer patients. Genomic and transcriptomic analyses of baseline and on-treatment biopsies demonstrated that concurrent radiation and immunotherapy increased the adaptative immune response while radiation alone decreased this response. Furthermore, high baseline aneuploidy predicted improved outcomes in patients treated with concurrent therapy. Expert Commentary: This study suggests that high tumor aneuploidy may be a biomarker of response to concurrent radiotherapy and immunotherapy and should be validated in future trials. Spurr LF, Martinez CA, Kang W, Chen M, Zha Y, Hseu R, et al. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer 2022;3:1498–512. The potential impact of... You do not currently have access to this content.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call